ArticleEuropean journal of pediatrics2026
Genetic and clinical spectrum of progressive familial intrahepatic cholestasis type 1: novel ATP8B1 variants and genotype-phenotype correlations.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive familial intrahepatic cholestasis type 1 (PFIC1) is a rare genetic disorder caused by variants in ATP8B1. The aim of this study was to characterize the clinical and genetic spectrum of PFIC1 and to investigate genotype-phenotype correlations in affected individuals. Clinical manifestations and laboratory findings from 15 newly identified individuals with PFIC1, together with data from 70 previously reported cases retrieved from the PubMed and CNKI databases, were collected and analyzed. A total of 10 novel pathogenic or likely pathogenic ATP8B1 variants were identified. Clinical manifestations included cholestatic jaundice, pruritus, hepatomegaly, diarrhea, deafness, and pancreatitis, accompanied by elevated serum transaminase, total/direct bilirubin, and total bile acid levels, with normal or low gamma-glutamyl transpeptidase (GGT) levels. Most patients with PFIC1 (71.2%, 42/59) showed an insufficient response to oral ursodeoxycholic acid (UDCA). Among patients who underwent liver transplantation (LT), severe postoperative complications, including hepatic steatosis (93.3%, 14/15) and intractable diarrhea (86.7%, 13/15), were common. In contrast, LT combined with surgical biliary diversion (SBD) reduced the incidence of these complications to 44.4% (4/9) for both outcomes. At the last follow-up, unfavorable clinical outcomes were observed in 64.7% (44/68) of cases. Compared with individuals carrying non-biallelic null ATP8B1 variants, those with biallelic null variants had an earlier age at onset, a lower response rate to UDCA, and reduced LT-free survival. Conclusion: This study described 15 new cases of PFIC1 carrying 10 novel ATP8B1 variants. PFIC1 involved multisystem manifestations, with normal-GGT cholestatic hepatitis representing a characteristic feature. The therapeutic efficacy of UDCA remained limited, and LT alone was associated with substantial postoperative complications, whereas combined LT and SBD appeared to reduce complication rates. Individuals with biallelic null ATP8B1 variants demonstrated earlier disease onset and poorer therapeutic and clinical outcomes.
Indexed as
Identifiers
42760445What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.